Market Assessment, Wet Age Related Macular Degeneration Current and Future Uptake of Anti VEGF Agents for Wet AMD Physician & Payer Forum China 2015 Report

How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy?

The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies targeting vascular endothelial growth factor (VEGF) are fairly successful in delaying the disease progression of wet AMD, a leading cause of blindness. Notable agents include Lucentis (Novartis’s ranibizumab), newly launched and locally manufactured Langmu (Chengdu Kanghong’s conbercept), and compounded Avastin (Roche’s bevacizumab), which is used off-label but is far less expensive than other agents in the class. However, none of the premium-priced anti-VEGF agents is included on the national or provincial drug formularies. To maximize opportunity in the Chinese market, developers of emerging therapies must carefully balance preferred pricing with uptake potential, especially when taking into account the availability of Avastin and local product Langmu, as well as the anticipated emergence of anti-VEGF biosimilars.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | China | 2015

Related Market Assessment Reports

Dry And Wet Age-Related Macular Degeneration – Geographic Focus-China – Dry And Wet Age-Related Macular Degeneration – China In-Depth (China)

Dry And Wet Age-Related Macular Degeneration – Geographic Focus-China – Dry And Wet Age-Related Macular Degeneration – China In-Depth (China)

Atopic Dermatitis / Atopic Eczema – Geographic Focus – China – Atopic Dermatitis/Atopic Eczema – China In-Depth (China )

Rheumatoid Arthritis – Geographic Focus – China – Rheumatoid Arthritis – China In-Depth (China)

Bladder Cancer And Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer And Upper Tract Urothelial Carcinoma | China In-Depth (China)